CNBX— CNBX Pharmaceuticals Inc.

Metric	FY2025	FY2024	FY2023	FY2022
Revenues	$0-100.0%	$130K-68.3%	$410K+1269.1%	$30K
Research and development expense	$0-100.0%	$195K-54.9%	$432K-63.5%	$1.2M
General and administrative expenses	$272K-47.6%	$518K-43.0%	$910K-49.5%	$1.8M
Total operating expenses	$272K-61.9%	$713K-46.8%	$1.3M-55.0%	$3.0M
Loss from operations	-$272K+53.4%	-$583K+37.4%	-$931K+68.5%	-$3.0M
Capital loss	$0-100.0%	$89K-96.7%	$2.7M	—
Financial loss, net	$42K+82.9%	$23K-56.1%	$53K+106.7%	-$782K
Net (loss) income	-$314K+54.8%	-$695K+81.3%	-$3.7M+0.3%	-$3.7M
Total comprehensive (loss) income	-$314K+54.8%	-$695K+81.3%	-$3.7M+15.5%	-$4.4M
Net (loss) per share - basic	$0.00+100.0%	-$0.02+95.2%	-$0.42	—
Net (loss) per share - diluted	$0.00+100.0%	-$0.02+95.2%	-$0.42	—
Weighted average number of shares outstanding - Basic	90.6M+199.7%	30.2M+242.8%	8.8M	—
Weighted average number of shares outstanding - Diluted	90.6M+199.7%	30.2M+242.8%	8.8M	—

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.